Abstract
Targeted therapy at NSCLC started thanks to the knowledge of EGFR mutations and development of connected targeted drugs. The first generation of these drugs has clearly demonstrated its effectiveness, but there is problem with formation of tumor resistence to this treatment.
Thus, there is an effort these properties affect by the expansion of the spectrum of blocking receptors on complete ErbB family (which includes EGFR). The first of the second generation drugs was afatinib, which demonstrated not only efficacy in delaying progression in first-line treatment of patients with EGFR mutations, but also improving the quality of life of these patients.